Sarepta Therapeutics, Inc.(SRPT)
$137.94▲5.7%
Market is closed - opens 8 PM, 29 Nov 2024
Insights
- Sarepta Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Sarepta Therapeutics, Inc. stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Sarepta Therapeutics, Inc. stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for Sarepta Therapeutics, Inc. stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 64.58 | Sell |
Stochastic | 91.9, 57.18 | Neutral |
Ultimate Oscillator | 76.67 | Sell |
Stochastic Relative Strength Index | 80.69, 65.87 | Neutral |
Moving Average Convergence Divergence | -2.3, -3.61 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 111.82 | Sell |
20 | 117.27 | Sell |
50 | 121.9 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 115.92 | Sell |
20 | 117.15 | Sell |
50 | 122.24 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 113.46 | Buy |
20 | 117.73 | Buy |
50 | 120.97 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 116.53 | Buy |
20 | 113.69 | Sell |
50 | 114.36 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 120.21 | Buy |
20 | 113.82 | Sell |
50 | 113.85 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 117.93 |
Resistance L2 | 116.62 |
Resistance L1 | 115.63 |
Pivot Point | 114.32 |
Support L1 | 113.33 |
Support L2 | 112.02 |
Support L3 | 111.03 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.